Innorna Press Releases

• Published on August 1, 2024 - 06:08 GMT

  

  Innorna Announces ODD Granted by the US FDA to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis

  UNITED STATES, August 1, 2024 /⁨EINPresswire.com⁩/ -- Innorna Announces Orphan Drug Designation Granted by the US FDA to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis Innorna, a clinical-stage biotech company pioneering its …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on July 24, 2024 - 21:41 GMT

  

  Innorna Receives IND Clearance for IN001 Herpes Zoster mRNA Vaccine in China

  UNITED STATES, July 24, 2024 /⁨EINPresswire.com⁩/ -- Innorna Receives IND Clearance for IN001 Herpes Zoster mRNA Vaccine in China. Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on July 23, 2024 - 07:42 GMT

  

  Innorna Announces the U.S. FDA Orphan Drug Designation Granted to IN022 for the Treatment of Homocystinuria

  UNITED STATES, July 23, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, today announced that the U.S. Food and Drug Administration (FDA …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on July 13, 2024 - 14:34 GMT

  

  Innorna Announces U.S. FDA RPDD Granted to IN016 for the Treatment of Progressive Familial Intrahepatic Cholestasis

  UNITED STATES, July 13, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, today announced that the U.S. Food and Drug Administration (the …

  Distribution channels: Business & Economy, Companies ...
• Published on July 9, 2024 - 06:59 GMT

  

  Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN022 for the Treatment of Homocystinuria

  UNITED STATES, July 9, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, announced a significant milestone today. The U.S. Food and Drug …

  Distribution channels: Business & Economy, Companies ...
• Published on June 14, 2024 - 00:55 GMT

  

  Innorna receives IND clearance for its first-in-class bivalent RSV mRNA vaccine in China

  IN006, a bivalent RSV vaccine developed by Innorna's proprietary mRNA-LNP technology, has broad-spectrum potency against both the A and B subgroups of RSV. UNITED STATES, June 13, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage biotech company …

  Distribution channels: Business & Economy, Companies ...
• Published on April 26, 2024 - 06:22 GMT

  

  Innorna's broad-spectrum SARS-CoV-2 mRNA vaccine receives Phase II clinical trial approval from the FDA

  FDA has approved Phase II trial for IN002.5.1 SARS-CoV-2 mRNA vaccine. This approval paves the way for the development of combined respiratory virus vaccines. MILLINGTON, NEW JERSEY, UNITED STATES, April 26, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a …

  Distribution channels: Business & Economy, Companies ...
• Published on February 3, 2024 - 14:07 GMT

  

  Innorna appointed Dr. Zhu Zhiqing as the Chief Technology Officer

  UNITED STATES, February 3, 2024 /⁨EINPresswire.com⁩/ -- Innorna officially announced the appointment of Dr. Zhiqing Zhu as the company's Chief Technology Officer (CTO). Dr. Zhu will oversee the company's CMC business. Zhiqing (Zach) received his …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on January 13, 2024 - 06:19 GMT

  

  Innorna Receives IND Clearance by FDA Enabling Phase I Initiation for Bivalent Respiratory Syncytial Virus mRNA Vaccine

  IN006, the first bivalent mRNA vaccine that targets both subtypes of RSV (A&B), comprises two mRNAs utilizing Innorna's proprietary pre-fusion F protein design. UNITED STATES, January 13, 2024 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage …

  Distribution channels: Business & Economy, Companies ...
• Published on October 3, 2023 - 23:18 GMT

  

  Innorna Receives IND Clearance by FDA Enabling Phase I Initiation for Herpes Zoster mRNA Vaccine

  Innorna focuses on developing best-in-class LNP delivery technology and advancing innovative RNA therapies to address unmet medical needs globally. UNITED STATES, October 3, 2023 /⁨EINPresswire.com⁩/ -- Innorna, a clinical-stage biotech company pioneering …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on June 1, 2022 - 19:00 GMT

  

  Qilu Pharmaceutical to present 4 posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

  CHICAGO, ILLINOIS, UNITED STATES, June 1, 2022 /⁨EINPresswire.com⁩/ -- Qilu Pharmaceutical will be presenting four of its pipeline products at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held on June 3-7, 2022 in Chicago, …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on April 8, 2022 - 13:00 GMT

  

  Qilu Pharmaceutical to present 7 posters at the Annual Meeting of the American Association of Cancer Research (AACR)

  Qilu Pharmaceutical to present 7 posters at the Annual Meeting of the American Association of Cancer Research (AACR) to be held on April 8-13, 2022 New Orleans. NEW ORLEANS, LA, UNITED STATES, April 8, 2022 /⁨EINPresswire.com⁩/ -- Qilu Pharmaceutical will …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...